Acuren Corp

The asset remains in a sustained Stage 4 decline, with both Long-Term and Medium-Term biases firmly bearish. Price is trading below declining EMAs and key SMAs, confirming continued supply dominance. Short-Term conditions are currently unfavorable for fresh sell entries, as price sits extended below moving averages. Execution should be limited to trimming on rally attempts into resistance zones to preserve capital in this downtrend.

• ↑Ambitious “3/18/85” framework targets $3B revenue, 18% EBITDA margin, 85% FCF by 2029 (11% CAGR)
• ↑NV5 merger expands service portfolio and boosts cross-sell potential in TIC sector
• ↓Negative earnings yield and P/E of -15.6 highlight profitability challenges